Status:
COMPLETED
A Bioequivalence Study of 15 mg ER OROS Paliperidone
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Conditions:
Schizophrenia
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the bioequivalence between the Phase 3 and the to-be-marketed formulations of extended release (ER) OROS paliperidone and to evaluate the effect of food on the...
Detailed Description
This study is designed as a single-center, open-label, randomized, 3 treatment-period, crossover study in healthy male adults. The study consists of a screening phase and an open-label treatment phase...
Eligibility Criteria
Inclusion
- Body Mass Index (weight \[kg\]/height \[m²\]) of 18 to 28 kg/m², inclusive
- Have a supine (after 5 minutes rest) blood pressure between the range of 100 to 140 mmHg systolic, inclusive, and 50 to 90 mmHg diastolic, inclusive
- Healthy on the basis of a prestudy physical examination, medical history, ECG, and the laboratory results of serum chemistry, hematology and urinalysis performed within 21 days before the first dose. If the results of the serum chemistry, hematology or urinalysis testing are not within the laboratory's reference ranges the volunteer can be included only if the investigator judges that the deviations are not clinically significant. For renal function tests, the values must be within the normal laboratory reference ranges.
Exclusion
- Drug allergy to risperidone, paliperidone, or any of its excipients
- Known allergy or history of significant hypersensitivity to heparin, in case a heparin lock will be used
- Recent history of alcohol or substance abuse, a positive test result for the urine drug screen at screening or upon admittance to the testing facility or a positive result for the alcohol urine test upon admittance to the testing facility
- Relevant history or presence of any cardiovascular (including myocardial infarct or cardiac arrhythmia), respiratory, neurologic (including seizures), psychiatric, renal, hepatic, gastrointestinal (including surgeries, severe gastrointestinal narrowing, and malabsorption problems), endocrine, hematologic or immunologic disease
- History of any cancer, with the exception of basal cell carcinoma
- At screening, has a sustained decrease of \>20 mmHg in systolic blood pressure or a decrease of \>10 mmHg in diastolic blood pressure after standing for at least 2 minutes that is not associated with an increase of \>15 beats per minute (bpm) in heart rate
- Bradycardia (heart rate \<50 bpm) as determined by screening ECG
- History of or a positive test result for any of the serology tests (hepatitis B, C, and HIV)
- History of smoking or use of nicotine-containing substances within the last 2 months, as determined by medical history and/or volunteer's verbal report. Volunteers must agree to refrain from use throughout the study
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00892489
Start Date
July 1 2004
End Date
December 1 2004
Last Update
June 8 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.